Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

The brown fat-enriched exosomal miR-206-3p attenuates hepatic lipogenesis by decreasing pentose phosphate pathway

Yang LJ., Tang QK., Wang L., Song YJ., Xu ZY., Ma XN.

Animal Study on Type 2 Diabetes, published in Life Metab (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Life Metab (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41070195
PMCID
PMC12507029
DOI
10.1093/lifemeta/loaf028

Abstract (original English)

Brown adipose tissue (BAT) orchestrates interorgan crosstalk through secreted mediators, including proteins, lipids, and exosomal microRNAs (miRNAs). However, the precise molecular identities and functional contributions of these mediators remain elusive. In this study, we isolated exosomes from BAT and conducted miRNA sequencing, identifying miR-206-3p as a previously unrecognized exosomal miRNA with the potential to alleviate metabolic dysfunction-associated fatty liver disease (MAFLD). In vivo , adipose-specific knockout of miR-206-3p in mice exacerbated obesity-induced MAFLD, glucose intolerance, insulin resistance, and impaired energy expenditure. Mechanistically, BAT-derived miR-206-3p is selectively packaged into exosomes via a BAT-specific "exo motif" and transported to the liver, where it targets the 3' untranslated regions (3'-UTRs) of glucose-6-phosphate dehydrogenase ( G6pd ) and transketolase ( Tkt ), which are key enzymes in the pentose phosphate pathway (PPP). The PPP generates nicotinamide adenine dinucleotide phosphate (NADPH) and ribulose-5-phosphate (Ru-5-P) to support lipogenesis and nucleotide synthesis. miR-206-3p modulates these processes by decreasing NADPH production to inhibit hepatic lipid synthesis and increasing Ru-5-P availability to promote cell proliferation. Notably, obese individuals exhibit reduced serum exosomal miR-206-3p alongside upregulat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research